{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:42:05Z","timestamp":1790224925787,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.cjca.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T12:48:19Z","timestamp":1447159699000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications"],"prefix":"10.1016","volume":"32","author":[{"given":"Michael N.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald V.","family":"Lacro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.11.003_bib1","first-page":"123","article-title":"A\u00a0prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment","volume":"129","author":"Halpern","year":"1971","journal-title":"Johns Hopkins Med J"},{"key":"10.1016\/j.cjca.2015.11.003_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.11.003_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0002-9149(94)90762-5","article-title":"Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome","volume":"74","author":"Salim","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0002-9149(99)00101-0","article-title":"Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome","volume":"83","author":"Rossi-Foulkes","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpeds.2006.09.003","article-title":"Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome","volume":"150","author":"Selamet Tierney","year":"2007","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2015.11.003_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.amjcard.2006.08.048","article-title":"Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome","volume":"99","author":"Ladouceur","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan\u2019s syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib8","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1111\/j.1651-2227.2011.02293.x","article-title":"The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan\u2019s syndrome: a meta-analysis","volume":"100","author":"Gao","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cjca.2015.11.003_bib9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jpeds.2014.07.008","article-title":"\u03b2-Blockers and angiotensin converting enzyme inhibitors: comparison of effects on aortic growth in pediatric patients with Marfan syndrome","volume":"165","author":"Phomakay","year":"2014","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2015.11.003_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1172\/JCI42014","article-title":"TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions","volume":"120","author":"Dietz","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2015.11.003_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nature10145","article-title":"Lessons on the pathogenesis of aneurysm from heritable conditions","volume":"473","author":"Lindsay","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2015.11.003_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.cjca.2015.11.003_bib13","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.11.003_bib14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.amjcard.2013.06.019","article-title":"Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome","volume":"112","author":"Pees","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/heartjnl-2013-304946","article-title":"Retrospective analysis of the effect of angiotensin II receptor blocker versus beta-blocker on aortic root growth in paediatric patients with Marfan syndrome","volume":"100","author":"Mueller","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2015.11.003_bib16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.11.003_bib17","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ahj.2013.02.019","article-title":"Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy","volume":"165","author":"Lacro","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.11.003_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.echo.2013.02.018","article-title":"Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome","volume":"26","author":"Selamet Tierney","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2015.11.003_bib19","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.11.003_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2459\/JCM.0b013e3283232a45","article-title":"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations","volume":"10","author":"Gambarin","year":"2009","journal-title":"J\u00a0Cardiovasc Med"},{"key":"10.1016\/j.cjca.2015.11.003_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-11-3","article-title":"Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial","volume":"11","author":"Radonic","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.cjca.2015.11.003_bib22","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.11.003_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acvd.2010.04.008","article-title":"Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome","volume":"103","author":"Detaint","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2015.11.003_bib24","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.11.003_bib25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.recesp.2011.02.009","article-title":"Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome","volume":"64","author":"Forteza","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2010.12.070","article-title":"The Ghent Marfan Trial\u2013a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers","volume":"157","author":"Moberg","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/1745-6215-14-408","article-title":"A\u00a0prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol","volume":"14","author":"Mullen","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.cjca.2015.11.003_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","article-title":"Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study","volume":"88","author":"Chiu","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2015.11.003_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1358863X15569868","article-title":"Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome","volume":"20","author":"Bhatt","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.cjca.2015.11.003_bib30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ijcard.2014.11.082","article-title":"A\u00a0randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes","volume":"179","author":"Sandor","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ahj.2015.01.011","article-title":"Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists\u2019 Collaboration","volume":"169","author":"Pitcher","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.11.003_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","article-title":"Revised diagnostic criteria for the Marfan syndrome","volume":"62","author":"De Paepe","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.cjca.2015.11.003_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCGENETICS.114.000950","article-title":"Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome","volume":"8","author":"Franken","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2015.11.003_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ng1511","article-title":"A\u00a0syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2","volume":"37","author":"Loeys","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2015.11.003_bib35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.amjcard.2005.01.032","article-title":"Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome","volume":"95","author":"Yetman","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.11.003_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jama.298.13.1539","article-title":"Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial","volume":"298","author":"Ahimastos","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2015.11.003_bib37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1365-2362.2012.02668.x","article-title":"Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial","volume":"42","author":"Williams","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjca.2015.11.003_bib38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.110.990549","article-title":"Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders","volume":"124","author":"Morris","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.11.003_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/CIRCULATIONAHA.114.014934","article-title":"Segmental aortic stiffness in children and young adults with connective tissue disorders: relationships with age, aortic size, rate of dilation, and surgical root replacement","volume":"132","author":"Prakash","year":"2015","journal-title":"Circulation"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15015792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15015792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T17:20:06Z","timestamp":1537204806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15015792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0828282X15015792"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.11.003","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}